Guide · Checked September 27, 2026
Who prescribed it, who dispensed it, and which testosterone product is it?
An online service, prescribing practice and pharmacy may have different roles. Keep the medicine’s identity and the right professional contacts clear.
Based on public documents · No clinician sign-off or firsthand treatment testing
The name on a website, the name on a card statement and the name on a pharmacy label may not be the same. That does not by itself mean something is wrong. It means the service involves different roles, and a question about the medicine may need to reach a different person from a question about the bill.
For injectable testosterone, a clear record helps keep those roles connected. This guide explains which identities matter and why evidence for a named product cannot automatically be assigned to an unspecified preparation. It does not teach injection technique, compare personal doses or determine whether a particular pharmacy or prescription is appropriate for you.
What this article covers
Separate the prescribing decision from dispensing and administration support
The prescribing clinician assesses the medical question and issues a prescription when appropriate. The dispensing pharmacy identifies and supplies the medicine under that prescription. A service company may arrange appointments, payments or communication, but a customer-support contact is not automatically the person who can explain a clinical decision or a formulation question.
Ask for the names and contact routes relevant to your actual care. Which practice holds the assessment? Which pharmacy will dispense? Who can clarify the medicine label? The FDA’s online-pharmacy guidance includes access to a licensed pharmacist among the features to look for. A general chat button should not be assumed to answer every kind of question.
Verify the pharmacy by its actual name
FDA provides a state-board license lookup resource for checking online pharmacies. Use the dispensing pharmacy’s name and location rather than assume that a telehealth brand is itself a pharmacy. FDA also advises checking for a prescription requirement, a physical US address and telephone contact, and a pharmacist who can answer questions.
Licensing is one important check, not proof of the suitability of an individual prescription or the approval status of a preparation. A phrase such as registered pharmacy should not be read as FDA approval of every item dispensed. If the service cannot yet identify the pharmacy for a proposed order, keep that as an unresolved question rather than supply a name from another patient’s experience.
Let the actual label settle the product identity
Keep the full medicine name, concentration, dispensing pharmacy and prescription information together. An advertisement may identify an active ingredient while leaving the manufacturer, excipients or container details unstated. A photograph on a sales page cannot replace the label that accompanies the actual medicine. Ask the pharmacist about an unclear name, difference or missing information.
CoreAge’s TRT page identifies testosterone cypionate 200 mg/mL. That is a concentration and does not tell a reader what amount to administer. Our CoreAge review examines the current public offer, including its unknown finished-product details. This guide deliberately provides no conversion from a concentration into syringe markings, volume or a treatment schedule.
Compounding changes what approval can be claimed
CoreAge explicitly describes its offer as compounded in the United States. FDA explains that compounded medicines are not FDA-approved and do not receive the agency’s premarket review for safety, effectiveness and quality. A clinician’s involvement or use of an ingredient found in an approved drug does not give a compounded finished product that approval.
This distinction does not establish that an unseen preparation is defective. It explains why the exact formulation and professional explanation matter. Ask the prescriber and pharmacist how the proposed medicine is identified and what patient information accompanies it. Do not infer ingredient compatibility, stability or equivalence from a broad assurance that a preparation is personalized.
Route and label dates belong to the identified product
The Pfizer Depo-Testosterone label concerns its specific intramuscular cypionate injection. CoreAge’s FAQ discusses intramuscular and subcutaneous options, but that does not make both routes approved for every product containing the same ester. Route and administration instructions need to come from the professionals responsible for the actual prescription.
Dates also matter. FDA’s current information reports requested labeling changes in June 2026, while the Pfizer document checked for this guide still carries a September 2025 revision. The June request included removal of the age-related limitation and revisions concerning prostate cancer and benign prostatic hyperplasia. A later class request and an earlier posted product document are not interchangeable records. Ask for current information relevant to the supplied medicine rather than choose whichever webpage seems most reassuring.
Know which questions need the pharmacist and which need the prescriber
The pharmacist is an important contact for identifying a medicine, its ingredients and dispensing instructions. The prescriber needs to assess the treatment’s purpose, response and any proposed change. Some questions require both, especially when a label seems inconsistent with what the clinician explained. Keep the original information available so they can reconcile it rather than asking the patient to choose between versions.
The Endocrine Society guideline calls for continuing evaluation of response and adverse effects. Medicine delivery does not complete that clinical review. Our lab and interpretation guide explains the related responsibility for test results. If a new concern is urgent, use the appropriate medical route explained by the care team rather than assume a routine shipping or customer-service channel is sufficient.
Preserve the record if the service or pharmacy changes
Retain the label and contact details with your assessment and laboratory records. Our provider-transfer guide explains how that material helps a receiving clinician understand previous care. A new service’s willingness to review records does not establish that it will supply an identical preparation or continue the same prescription.
The service comparison addresses advertised arrangements rather than auditing individual pharmacies. The material was prepared for the CoreAge Rx network. That publishing relationship deserves consideration when interpreting company coverage, and should not be mistaken for pharmacy certification, treatment endorsement or evidence of comparative quality. A useful medicine record makes the actual product and responsible professionals identifiable, so clinical and dispensing questions reach the people able to answer them.
Source documents
Read each document beside the claim it supports. A provider’s offer, a clinical guideline and an exact medicine label are different kinds of evidence.
- FDA BeSafeRx: Considering an Online Pharmacy?Federal pharmacy information · Accessed 2026-09-27
- FDA BeSafeRx: Locate a State-Licensed Online PharmacyFederal pharmacy verification resource · Accessed 2026-09-27
- CoreAge Rx: Injectable TRT public offerProvider product and service page · Accessed 2026-09-27
- FDA: Understanding the Risks of Compounded DrugsRegulatory explanation · Accessed 2026-09-27
- Pfizer: Depo-Testosterone prescribing information, revised September 2025Exact product labeling · Accessed 2026-09-27
- FDA: Testosterone Information and June 2026 requested labeling changesCurrent regulatory information · Accessed 2026-09-27
- Endocrine Society: Testosterone Therapy in Men With Hypogonadism, 2018 guidelineClinical practice guideline · Accessed 2026-09-27